The pipeline progress—especially in targeted alpha therapy with MP0712—provides potential long-term value, but near-term fundamentals remain weak due to lack of revenue and continued losses. Traders should monitor upcoming clinical data readouts in 2026 as key catalysts.
Price Chart
Executive Summary
Molecular Partners reported its 2025 financial results and provided updates on its clinical pipeline, including the initiation of a Phase 1/2a trial for its lead Radio-DARPin candidate MP0712, ongoing clinical development of MP0317 and MP0533, and a strengthened financial runway through 2028. Despite no revenue and a net loss of CHF 61.7 million, the company advanced key oncology programs and reduced operating expenses year-over-year.
Key Financial Metrics
Key Facts
- No revenue in 2025 (down from CHF 5.0M in 2024)
- Net loss widened to CHF 61.7M in 2025 from CHF 54.0M in 2024
- Cash position decreased to CHF 93.1M from CHF 149.4M, but provides runway until 2028
- Operating expenses declined to CHF 58.1M from CHF 66.2M in 2024
- Phase 1/2a trial of MP0712 (DLL3-targeting Radio-DARPin) initiated; initial data expected in 2026
- MP0317 Phase 2 trial in cholangiocarcinoma ongoing; MP0533 AML trial update expected in H1 2026
- Appointed new CSO and formed Scientific Advisory Board to guide radiotherapeutics development
Financial Impact
Revenue declined by CHF 5.0 million YoY; net loss increased by CHF 7.7 million; operating cash outflow reduced by CHF 7.9 million
Risk Factors
- No near-term revenue generation; reliance on cash runway until potential inflection points in 2026+
- Clinical development risk in early-stage oncology programs with high failure rates
- Dilution risk likely before 2028 given current cash burn trajectory
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255073 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers